Kristie Blum is an Oncology physician affiliated with Emory University. OpenAlex indexes 405 publications with 22,073 citations (h-index 61); ClinicalTrials.gov lists 13 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1365c Clifton Rd NE
Atlanta, GA 303221280
Telephone
404-778-1900Registry record last updated 21 Jul 2022.
Clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Sponsor: National Cancer Institute (NCI)
- Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Sponsor: Ohio State University Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ViiV Healthcare CompanyProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
63.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor63.9%Valacyclovir100%Part D≥16 patientsMetabolism & gastrointestinal
22.7%Proton pump inhibitor11.3%Pantoprazole Sodium100%Part D<11 patientsCorticosteroid11.3%Prednisone100%Part D<11 patientsCancer & immunology
13.4%Kinase inhibitor13.4%Brukinsa100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2017–2019 per NIH RePORTER. The latest:
- Development of a comprehensive research program in mantle cell lymphoma in the ibrutinib era
Emory University
FY2019$174,691K24CA201524 - Development of a comprehensive research program in mantle cell lymphoma in the ibrutinib era
Emory University
FY2018$176,011K24CA201524 - Development of a comprehensive research program in mantle cell lymphoma in the ibrutinib era
Emory University
FY2017$177,298K24CA201524
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Guyton, MD
Emory University
Keith Delman, MD
Emory University
Paolo Raggi, MD
Emory University
Monica Farley, MD
Emory University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”